KR920700623A - 에어로솔 담체 - Google Patents

에어로솔 담체

Info

Publication number
KR920700623A
KR920700623A KR1019910701180A KR910701180A KR920700623A KR 920700623 A KR920700623 A KR 920700623A KR 1019910701180 A KR1019910701180 A KR 1019910701180A KR 910701180 A KR910701180 A KR 910701180A KR 920700623 A KR920700623 A KR 920700623A
Authority
KR
South Korea
Prior art keywords
carrier
composition according
dry powder
mixed
granular
Prior art date
Application number
KR1019910701180A
Other languages
English (en)
Inventor
게인데르톤 데이빗
모하메드 카셈 누하
Original Assignee
데레크 리차드 찬들러
내셔날 리서치 디벨로프먼트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데레크 리차드 찬들러, 내셔날 리서치 디벨로프먼트 코포레이션 filed Critical 데레크 리차드 찬들러
Publication of KR920700623A publication Critical patent/KR920700623A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

에어로솔 담체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 평균입도가 5.0 내지 1000미크론이고 주름도가 1.75미만인, 건조분말 흡입 조성물에 사용하기에 적당한 과립 담체.
  2. 제1항에 있어서, 담체가 과립 결정성 당인 것을 특징으로 하는 담체.
  3. 제2항에 있어서, 결정성 당이 글루코오스, 프록토오스, 만니톨, 수크로오스 및 락토오스로 이루어지는 군으로 부터 선택되는 것을 특징으로 하는 담체.
  4. 제3항에 있어서, 결정성 당이 락토오스인 것을 특징으로 하는 담체.
  5. 제1항 내지 4항중 어느 한 항에 있어서, 입자의 평균 입도가 30 내지 25미크론인 것을 특징으로 하는 담체.
  6. 제1항 내지 5항중 어느 한 항에 있어서, 입자의 주름도가 1.5보다 작은 것을 특징으로 하는 담체.
  7. 하나 이상의 약리학적 제제와 혼합된 형태의 부형제로 이루어지느 건조분말 흡입 조성물로서, 부형제가 제1항 6항중 어느 한 항의 과립 담체를 포함하는 것을 특징으로 하는 건조 분말 흡입 조성물.
  8. 제7항에 있어서, 부형제가 제1항 내지 6항중의 어느 한 항의 과립담체로 80중량%이상 포함하는 것을특징으로 하는 조성물.
  9. 제8항에 있어서, 부형제거 본질적으로 제1항 내지 6항중 어느 한 항의 과립 담체로 구성되는 것을 특징으로 하는 조성물.
  10. 제7항 내지 9항중 어느 한 항 에 있어서, 0.1내지 50중량%의 약리학적 제제를 포함하는 것을 특징으로 하는 조성물.
  11. 제6항 내지 10항중 어느 한 항 에 있어서, 약리학적 제제가 0.1내지 10.0미크론의 평균입도를 가지고 있는 과립고체인 것을 특징으로 하는 조성물.
  12. 제6항 내지 11항중 어느 한 항 에 있어서, 약리학적 제제가 β-아고니스트, 스테로이드 또는 크로모글리코산 나타륨인 것을 특징으로 하는 조성물.
  13. 제6항 내지 11항중 어느 한 항 에 있어서, 약리학적 제제가 펩티드인 것을 특징으로 하는 조성물.
  14. 제13항 에 있어서, 약리학적 제제가 인슐린 및 ACTH 및 LNRH 유사체같은 성장 호르몬을 포함하는 군으로 부터 선택되는 것을 특징으로 하는 조성물.
  15. 제6항 내지 11항중 어느 한 항에 있어서, 약리학적 제제가 항박티레아제제인 것을 특징으로 하는 조성물.
  16. 제15항 에 있어서, 항박티레아제제가 펜타미딘인 것을 특징으로 하는 조성물.
  17. 물과 혼합될 수 없는 최소한 동등부피의 유기용매, 및 수용액 부피의 5부피% 이상의, 물과 혼합될 수 없는 용매 및 물과 혼합할 수 있는 일정량의 용매를 첨가함에 의하여 포화 수용액으로부터 담체를 침전시키는 것으로 이루어지는, 제1항 내지 제6항 중 어느 한 한의 과립담체의 제조방법.
  18. 제16항 에 있어서, 물과 혼합될 수 없는 용매는 헥산, 클로로포름, 시클로헥산 및 톨루엔으로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.
  19. 제17항 또는 제18항에 있어서, 물과 혼합될 수 있는 용매는 아세톤, 에탄올, 프로판올 또는 부탄올 및 아세토니트릴로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 방법.
  20. 제7항 내지 14항중 어느 한 항에 따르는 캡슐화된 건조 분말 흡입 조성물.
  21. 제7 내지 14항 또는 20항중 어느 한 항에 따르는 건조 분말 흡입 조성물을 함유하는 것을 특징으로 하는 건조분말 흡입기.
  22. 전술한 실시예를 참조로 실제로 지금까지 기재된 제1항의 담체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910701180A 1990-01-24 1991-01-24 에어로솔 담체 KR920700623A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909001635A GB9001635D0 (en) 1990-01-24 1990-01-24 Aerosol carriers
GB90016353 1990-01-24
PCT/GB1991/000103 WO1991011179A1 (en) 1990-01-24 1991-01-24 Aerosol carriers

Publications (1)

Publication Number Publication Date
KR920700623A true KR920700623A (ko) 1992-08-10

Family

ID=10669832

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701180A KR920700623A (ko) 1990-01-24 1991-01-24 에어로솔 담체

Country Status (15)

Country Link
US (1) US5254330A (ko)
EP (1) EP0464171B1 (ko)
JP (1) JP3100626B2 (ko)
KR (1) KR920700623A (ko)
AT (1) ATE98487T1 (ko)
AU (1) AU635616B2 (ko)
CA (1) CA2049302C (ko)
DE (1) DE69100792T2 (ko)
FI (1) FI914460A0 (ko)
GB (2) GB9001635D0 (ko)
HU (1) HUT59821A (ko)
IE (1) IE910222A1 (ko)
NO (1) NO913731L (ko)
PT (1) PT96567A (ko)
WO (1) WO1991011179A1 (ko)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007855A1 (en) * 1987-04-09 1988-10-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
EP0630230B1 (en) * 1992-03-10 1996-12-04 FISONS plc Pharmaceutical inhalation compositions
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US5536249A (en) * 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5641510A (en) * 1994-07-01 1997-06-24 Genentech, Inc. Method for treating capsules used for drug storage
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE236617T1 (de) 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ATE238043T1 (de) * 1994-12-22 2003-05-15 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
AU1860697A (en) * 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
FR2742164B1 (fr) * 1995-12-11 1999-01-29 Beghin Say Eridania Sucre microcristallin : composition et methode d'obtention
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
US5976574A (en) 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
SE9701956D0 (sv) 1997-05-23 1997-05-23 Astra Ab New composition of matter
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
NZ504711A (en) * 1997-12-03 2002-02-01 Fujisawa Pharmaceutical Co Soft-pellet drug and process for the preparation thereof
GB9806477D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved crystals
US6489183B1 (en) * 1998-07-17 2002-12-03 Micron Technology, Inc. Method of manufacturing a taped semiconductor device
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
EP1131059B1 (de) 1998-11-13 2003-03-05 Jago Research Ag Trockenpulver zur inhalation
JP2002532405A (ja) * 1998-12-11 2002-10-02 ファルマヘミー ベー.フェー. オピオイド吸入製剤
ATE289825T1 (de) 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
DK2280020T3 (en) 1999-06-29 2016-05-02 Mannkind Corp Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ITMI991582A1 (it) * 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
EP1604024A4 (en) * 2000-04-06 2008-04-23 Wayne P Franco METHODS OF USING GROWTH FACTORS FOR TREATING CARDIOPATHY
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002007705A1 (en) * 2000-07-20 2002-01-31 Campina B.V. Carrier material for dry powder inhalation
ATE320242T1 (de) * 2000-10-09 2006-04-15 3M Innovative Properties Co Medizinische aerosolzusammensetzung
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
DE10141376A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2005506323A (ja) * 2001-09-05 2005-03-03 ベクトゥラ・リミテッド 経口送達用機能性散剤
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
CA2468958C (en) 2001-12-19 2012-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
AU2002308143A1 (en) * 2002-04-12 2003-10-27 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
EP1501479A1 (en) * 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
AU2003233119A1 (en) * 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
GB0210527D0 (en) * 2002-05-08 2002-06-19 Univ Bath Process for the treatment of particles for use in pharmaceutical formulations
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1699435A4 (en) * 2003-09-18 2009-05-20 Norton Healthcare Ltd PARTICLE
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
JP2007534693A (ja) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するdpi製剤
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1858528A2 (en) * 2005-02-10 2007-11-28 Glaxo Group Limited Process for crystallizing lactose particles for use in pharmaceutical formulations
MX2007009656A (es) 2005-02-10 2007-11-07 Glaxo Group Ltd Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
WO2007019229A1 (en) * 2005-08-05 2007-02-15 3M Innovative Properties Company Compositions exhibiting improved flowability
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル, インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
JP2010500356A (ja) * 2006-08-09 2010-01-07 グラクソ グループ リミテッド ラクトースの製造方法
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
AR072114A1 (es) 2008-06-13 2010-08-04 Mannkind Corp Un inhalador de polvo seco y sistema para suministro de farmacos
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
TR201007250A2 (tr) 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012282936B2 (en) * 2011-07-08 2016-11-10 Pfizer Limited Process for the preparation of fluticasone propionate form 1
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE292149C (ko) *
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
GB2077100B (en) * 1980-04-30 1985-04-24 Fisons Ltd Pharmaceutical compositions containing cromoglycates
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
WO1991011179A1 (en) 1991-08-08
JPH04504427A (ja) 1992-08-06
NO913731D0 (no) 1991-09-23
AU635616B2 (en) 1993-03-25
GB2240337A (en) 1991-07-31
NO913731L (no) 1991-11-21
HUT59821A (en) 1992-07-28
EP0464171A1 (en) 1992-01-08
GB9101551D0 (en) 1991-03-06
US5254330A (en) 1993-10-19
AU7155991A (en) 1991-08-21
CA2049302A1 (en) 1991-07-25
DE69100792D1 (de) 1994-01-27
PT96567A (pt) 1991-10-15
GB9001635D0 (en) 1990-03-21
JP3100626B2 (ja) 2000-10-16
FI914460A0 (fi) 1991-09-23
CA2049302C (en) 2001-05-29
HU913284D0 (en) 1992-01-28
DE69100792T2 (de) 1994-04-14
GB2240337B (en) 1993-02-24
ATE98487T1 (de) 1994-01-15
IE910222A1 (en) 1991-07-31
EP0464171B1 (en) 1993-12-15

Similar Documents

Publication Publication Date Title
KR920700623A (ko) 에어로솔 담체
US3004894A (en) Therapeutic composition comprising tetracycline and a dioxolane
NO842291L (no) Fremgangsmaate for fremstilling av orale antidiabetiske substanser.
WO2002015937A2 (de) Pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend polyol-fettsäure-ester
CA2341568A1 (en) Stabilized pharmaceutical composition in lyophilized form
JPS61165322A (ja) スパガリン類の注射用凍結乾燥製剤
ATE40291T1 (de) Sphaerische einkristalle fuer pharmazeutische zwecke.
RU2001108569A (ru) Стабилизированная фармацевтическая композиция в лиофилизированной форме
CA2085344A1 (en) Injectable Pharmaceutical Composition
KR890009975A (ko) 신규의 시클로스포린 결정 형태, 이것의 제조방법 및 이것을 함유한 약학 조성물 및 그 용도
FR2649110B1 (fr) Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1001799B1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
FI83476B (fi) Foerfarande foer framstaellning av en beredning av 7 -difluorometyltioacetamido-7 -metoxi-3-/1-(2 -hydroxialkyl)-1h-tetrazol-5-yl/tiometyl-1-detia-1-oxa-3-cefem-4 -karboxisyra.
CH642085A5 (de) Verfahren zur gewinnung der polaren fraktion mit antipsoriatischer wirksamkeit eines extraktes aus farnpflanzen sowie ein gemaess diesem verfahren hergestelltes praeparat.
ATE129150T1 (de) Verfahren zur galenischen herstellung eines therapeutischen mittels, insbesondere auf aspirinbasis.
WO1993017691A3 (en) Pharmaceutical compositions containing monosialoganglioside gm1 or a derivative thereof suitable for the treatment of parkinson's disease
ATE24398T1 (de) Arzneimittelformulierung zur oralen verabreichung mit gehalt an einem glycosid antibiotikum und einem hilfsstoff.
Ogawa et al. Nuclear changes produced by bleomycin in the 3-methylcholanthrene-induced mouse epidermal carcinoma cells
JPH049336A (ja) 催眠剤
CA1075230A (en) Process for preparing solid sodium amoxycillin
KR950010155B1 (ko) 속용해성 주사용 세프피라마이드 제제
Uebel et al. Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes
JPS6440427A (en) 5-lipoxygenase action inhibitor
KR920017652A (ko) 신경보호활성을 갖는 α-디하이드로 에르고크립틴 약제학적 제제
ES8707108A1 (es) Procedimiento para la fabricacion de particulas de polvo micronizadas e hidrofilizadas de una substancia hidrofoga o dificilmente soluble, mezclados con un tensioactivo

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid